Cardiff ECMC aims to develop biomarkers, novel therapeutic approaches to cancer treatment and expand tissue banking. The Centre has a particular focus on acute myeloid leukaemia (AML) and conducts pre-clinical testing of novel agents that could lead to new treatments for the disease. Another focus area is translating knowledge of molecular pathways into biomarkers for breast cancer.
Clinical Focus Area
- Testing novel therapies for AML and CLL
- Biobanking for clinical trials
- Mutational analysis in AML, colorectal and prostate cancer
- PD markers in support of NCRI Group AML Trials
Scientific Focus Area
- Pre-clinical identification and testing of novel agents for AML
- In vitro models of endocrine resistance in breast cancer
- Maintenance of the national AML biobank
- Biomarkers in breast cancer
- GWAS studies
Disease Focus Area
For further information on the goals and objectives of Cardiff ECMC go to:
Cardiff ECMC principal investigators and staff have a diverse range of skills and expertise.
Cardiff ECMC has access to a range of research facilities that are utilised in studies.